Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $596,404.80 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 59,880 shares of the stock in a transaction that occurred on Thursday, July 23rd. The shares were bought at an average price of $9.96 per share, for a total transaction of $596,404.80. Following the transaction, the director owned 17,242,483 shares of the company’s stock, valued at $171,735,130.68. This trade represents a 0.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. bought 41,319 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.99 per share, with a total value of $412,776.81.
• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. purchased 120,582 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $10.43 on Friday. The business’s fifty day moving average is $8.96 and its 200 day moving average is $7.49. The company has a market capitalization of $257.80 million, a PE ratio of -2.95 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

ARTV has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Needham & Company LLC reiterated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wedbush lifted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Prelude Capital Management LLC purchased a new position in Artiva Biotherapeutics during the third quarter worth $41,000. Bank of America Corp DE raised its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth about $53,000. Qube Research & Technologies Ltd purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $58,000. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.